ВАШКУНСЕЛУШ Теофилу Кардозу Ди,САНТУШ ЛИМА Рикарду Жоржи Дуж,КАМПУШ КОШТА Руй Сердейра Ди,КОШТА БАРРУКАШ Педру Мигел Да,КАШТРУ ПЕРЕЙРА Лижия София Ди
申请号：
RU2012113844
公开号：
RU2012113844A
申请日:
2010.09.10
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. An oral suspension dosage form comprising a therapeutically effective amount eslikarbazepina acetate and a pharmaceutically acceptable liquid carrier.2. A dosage form according to claim 1, further comprising a suspending agent.3. A dosage form according to claim 2 wherein the suspending agent is xanthan gum.4. A dosage form according to claim 2 wherein the suspending agent is present in an amount ranging from 0.1 to 0.5 wt. / Vol.% Of the formulation.5. A dosage form according to any of the preceding claims, further comprising a wetting agent.6. A dosage form according to claim 5, wherein the wetting agent is a polyoxyethylene stearate.7. A dosage form according to claim 6, wherein the wetting agent is a polyoxy-100-stearate.8. A dosage form according to claim 5, wherein the wetting agent is present in an amount of 0.05 to 5 wt. / Vol.% Of the formulation.9. A dosage form according to any one of claims 1-4, 6, 7 or 8, further comprising an antimicrobial agent.10. A dosage form according to claim 9, wherein the antimicrobial agent comprises methylparaben and / or propylparaben.11. A dosage form according to claim 9, wherein the antimicrobial agent is present in an amount ranging from 0.1 to 0.5 wt. / Vol.% Of the formulation.12. The dosage form of claim 10 wherein the antimicrobial agent is present in an amount of from 0.1 to 0.5 wt. / Vol.% Of the formulation.13. A dosage form according to any one of claims 1-4, 6, 7, 8, 10, 11 or 12 wherein the liquid carrier is present in an amount of from 85 to 95 wt. / Vol.% Of the formulation.14. A dosage form according to any one of claims 1-4, 6, 7, 8, 10, 11 or 12 wherein the liquid carrier comprises a buffer solution having a pH in the range from 6.8 to 7.0.15. A dosage form according to claim 14, wherein the buffer solution is present in an amount of from 50 to 90% of the liquid carrier.16. A dosage form according to any one of claims 1-4, 6, 7, 8, 10, 11, 12 or 15, wherein the liquid carrier comprises an aqueous sorbit
